Eagle Health Investments LP Buys New Shares in MoonLake Immunotherapeutics $MLTX

Eagle Health Investments LP bought a new stake in MoonLake Immunotherapeutics (NASDAQ:MLTX) in the 4th quarter, Holdings Channel reports. The firm bought 187,600 shares of the company’s stock, valued at approximately $2,473,000. MoonLake Immunotherapeutics makes up approximately 0.5% of Eagle Health Investments LP’s portfolio, making the stock its 26th largest holding.

Other hedge funds and other institutional investors have also made changes to their positions in the company. FNY Investment Advisers LLC bought a new position in shares of MoonLake Immunotherapeutics in the third quarter valued at $28,000. Bank of America Corp DE boosted its position in MoonLake Immunotherapeutics by 64.7% during the third quarter. Bank of America Corp DE now owns 4,532 shares of the company’s stock worth $32,000 after purchasing an additional 1,781 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in MoonLake Immunotherapeutics by 115.0% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,919 shares of the company’s stock worth $42,000 after purchasing an additional 3,166 shares during the period. Covestor Ltd bought a new position in MoonLake Immunotherapeutics during the third quarter worth $46,000. Finally, BNP Paribas Financial Markets boosted its position in MoonLake Immunotherapeutics by 18.9% during the third quarter. BNP Paribas Financial Markets now owns 7,296 shares of the company’s stock worth $52,000 after purchasing an additional 1,158 shares during the period. 93.85% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have commented on MLTX. Needham & Company LLC lifted their price objective on shares of MoonLake Immunotherapeutics from $25.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, May 12th. Wolfe Research raised shares of MoonLake Immunotherapeutics from an “underperform” rating to an “outperform” rating and lifted their price objective for the stock from $12.00 to $24.00 in a research report on Monday, March 23rd. Oppenheimer lifted their price objective on shares of MoonLake Immunotherapeutics from $30.00 to $35.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 24th. Zacks Research raised shares of MoonLake Immunotherapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. Finally, HC Wainwright lifted their price objective on shares of MoonLake Immunotherapeutics from $40.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, May 11th. Nine research analysts have rated the stock with a Buy rating, four have given a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $23.85.

Insider Transactions at MoonLake Immunotherapeutics

In other news, CEO Da Silva Jorge Santos sold 51,873 shares of the business’s stock in a transaction dated Monday, April 13th. The shares were sold at an average price of $18.23, for a total value of $945,644.79. Following the completion of the sale, the chief executive officer owned 2,924,893 shares of the company’s stock, valued at approximately $53,320,799.39. The trade was a 1.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Bvf Partners L. P/Il sold 3,750,000 shares of the business’s stock in a transaction dated Tuesday, March 31st. The shares were sold at an average price of $16.79, for a total transaction of $62,962,500.00. Following the completion of the sale, the director directly owned 1,039,238 shares of the company’s stock, valued at approximately $17,448,806.02. The trade was a 78.30% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 3,900,000 shares of company stock valued at $65,714,663. 12.02% of the stock is currently owned by company insiders.

MoonLake Immunotherapeutics Trading Up 4.2%

MLTX stock opened at $17.05 on Thursday. MoonLake Immunotherapeutics has a one year low of $5.95 and a one year high of $62.75. The company has a debt-to-equity ratio of 0.39, a current ratio of 8.60 and a quick ratio of 8.60. The stock has a market cap of $1.22 billion, a price-to-earnings ratio of -4.41 and a beta of 1.01. The company has a fifty day moving average price of $17.41 and a two-hundred day moving average price of $15.70.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last announced its earnings results on Monday, May 11th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.07). Equities analysts anticipate that MoonLake Immunotherapeutics will post -3.71 EPS for the current year.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.